Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
Aims. To study the dynamics of body weight, waist circumference, blood lipid and insulin demand in patients with type 2 diabetes mellitus (T2DM) during first year of combined treatment with metformin and insulin analogues, compared with insulin analogue monotherapy. Materials and Methods. We exami...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2013-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/3596 |
| _version_ | 1826588086961700864 |
|---|---|
| author | Tatiana Ivanovna Romantsova T Sh Dzhavakhishvili O V Roik |
| author_facet | Tatiana Ivanovna Romantsova T Sh Dzhavakhishvili O V Roik |
| author_sort | Tatiana Ivanovna Romantsova |
| collection | DOAJ |
| description | Aims. To study the dynamics of body weight, waist circumference, blood lipid and insulin demand in patients with type 2 diabetes mellitus (T2DM) during first year of combined treatment with metformin and insulin analogues, compared with insulin analogue monotherapy. Materials and Methods. We examined 78 patients with T2DM on newly initiated insulin therapy, including 54 females and 24 males. Median age was 56 [51.0; 64.0] years, median disease duration ? 9 [6.8;14.0] years. Participants were subdivided in two groups. First group was comprised of 48 subjects (33 females and 15 males), who received monotherapy with insulin analogues (glargine, de- temir, biphasic Aspart 30 and Humalog Mix 25 or rapid-acting lispro and aspart). Second group included 30 patients (18 females and12 males), who were treated with combined therapy (insulin analogues plus metformin). We measured HbA1c, plasma lipid composition, BMI, waist circumference and insulin demand initially and after one year of follow-up. Results. We showed that combined therapy vs. insulin monotherapy allows better glycemic compensation while reducing insulin demand and lowering risks for weight gain. Conclusions. Combined insulin analogue plus metformin treatment delivers better metabolic control in patients with T2DM and is as- sociated with lower risks for body weight gain and increase in insulin demand against monotherapy with insulin analogues. |
| first_indexed | 2024-03-08T15:20:54Z |
| format | Article |
| id | doaj.art-036d8227a68a44eca926ab8e0dc1657b |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2025-03-14T16:35:45Z |
| publishDate | 2013-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-036d8227a68a44eca926ab8e0dc1657b2025-02-21T09:29:31ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782013-03-01161485110.14341/2072-0351-35963566Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatmentTatiana Ivanovna Romantsova0T Sh Dzhavakhishvili1O V Roik2I.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, MoscowI.M. Sechenov First Moscow State Medical University, MoscowAims. To study the dynamics of body weight, waist circumference, blood lipid and insulin demand in patients with type 2 diabetes mellitus (T2DM) during first year of combined treatment with metformin and insulin analogues, compared with insulin analogue monotherapy. Materials and Methods. We examined 78 patients with T2DM on newly initiated insulin therapy, including 54 females and 24 males. Median age was 56 [51.0; 64.0] years, median disease duration ? 9 [6.8;14.0] years. Participants were subdivided in two groups. First group was comprised of 48 subjects (33 females and 15 males), who received monotherapy with insulin analogues (glargine, de- temir, biphasic Aspart 30 and Humalog Mix 25 or rapid-acting lispro and aspart). Second group included 30 patients (18 females and12 males), who were treated with combined therapy (insulin analogues plus metformin). We measured HbA1c, plasma lipid composition, BMI, waist circumference and insulin demand initially and after one year of follow-up. Results. We showed that combined therapy vs. insulin monotherapy allows better glycemic compensation while reducing insulin demand and lowering risks for weight gain. Conclusions. Combined insulin analogue plus metformin treatment delivers better metabolic control in patients with T2DM and is as- sociated with lower risks for body weight gain and increase in insulin demand against monotherapy with insulin analogues.https://www.dia-endojournals.ru/jour/article/view/3596diabetes mellitus type 2insulin therapyinsulin analoguesmetformin |
| spellingShingle | Tatiana Ivanovna Romantsova T Sh Dzhavakhishvili O V Roik Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment Сахарный диабет diabetes mellitus type 2 insulin therapy insulin analogues metformin |
| title | Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment |
| title_full | Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment |
| title_fullStr | Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment |
| title_full_unstemmed | Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment |
| title_short | Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment |
| title_sort | effects of metformin on body weight in patients with type 2 diabetes mellitus receiving insulin analogue treatment |
| topic | diabetes mellitus type 2 insulin therapy insulin analogues metformin |
| url | https://www.dia-endojournals.ru/jour/article/view/3596 |
| work_keys_str_mv | AT tatianaivanovnaromantsova effectsofmetforminonbodyweightinpatientswithtype2diabetesmellitusreceivinginsulinanaloguetreatment AT tshdzhavakhishvili effectsofmetforminonbodyweightinpatientswithtype2diabetesmellitusreceivinginsulinanaloguetreatment AT ovroik effectsofmetforminonbodyweightinpatientswithtype2diabetesmellitusreceivinginsulinanaloguetreatment |